• Vaccine Name: DNA vaccine expressing the E2 protein
• Target Pathogen: Classical swine fever virus
• Target Disease: Classical swine fever, hog cholera
• Vaccine Ontology ID: VO_0004514
• Type: Live, attenuated vaccine
• Status: Licensed
• E2 gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid: pcDNA3.1 DNA vaccine plasmid
  • DNA vaccine plasmid name: pcDNA3.1 DNA vaccine plasmid
  • DNA vaccine plasmid VO ID: VO_0000158
• Immunization Route: Intramuscular injection (i.m.)

Pig Response

• Vaccination Protocol: Groups of 3 pigs were used in each experimental group. Briefly, group 1 (pE2) was inoculated with 500 μg of plasmid pE2 in co-injection with 500 μg of pcDNA3.1 (empty plasmid, Invitrogen), group 2 (pE2 + pCCL20) was inoculated with 500 μg pE2 in co-injection with 500 μg of pCCL20, and the control group was injected with PBS. In all cases, three doses were administered intramuscularly in the neck every 12 days. Before every immunization (at days 0, 12 and 24), pigs were bled to follow the CSFV specific immunoresponse (Tarradas et al., 2011).
• Vaccine Immune Response Type: VO_0000286
• Immune Response: The vaccine is able to increase antibody-mediated responses, while enhancing the T helper cell response associated with the induction of neutralizing antibodies against CSFV (Tarradas et al., 2011).
• Challenge Protocol: Thirty-six days after the first immunization (pre-challenge), all pigs were challenged with 10^5 DICT50 of CSFV virulent Margarita strain by i.m. injection in the neck (Tarradas et al., 2011).
• Efficacy: Immunized animals with E2 DNA vaccine in co-administration with the plasmid containing swine CCL20 developed high titers of neutralizing antibodies against homologous and heterologous CSFV strains, and were totally protected upon a lethal viral challenge (Tarradas et al., 2011).